Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update

Sonnet BioTherapeutics Provides Fiscal Year 2021 Third Quarter Business and Earnings Update

  • Expanded F H AB Intellectual Property Portfolio

  • Completed $15.9 million At-The-Market Financing

  • SON-1010 and SON-080 on track for IND submissions by calendar year end

PRINCETON, NJ / ACCESSWIRE / August 16, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (“Sonnet” or the “Company”), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended June 30th , 2021 and provided a business update.

“Throughout the quarter, we’ve continued to make several advancements towards the clinic with our proprietary Fully Human Albumin

Read more